About Cenyx
Located in Seoul, South Korea, cosmetic lab Cenyx advances nanomedicine through its proprietary CX synthesis platform. Since 2016, the lab specializes in:
- Nanozyme development for inflammatory diseases
- Biotech agents for nervous system treatments
- Clinical research and drug pipeline programs
- Enzymatic reaction optimization
With orphan drug designation granted in 2025, Cenyx continues expanding its therapeutic applications in the growing South Korean biotech sector.
Frequently asked questions
Cenyx focuses on the following areas:
- Nanozyme Technology
- CX synthesis platform
- Nano-biotech agents
- Enzymatic reaction catalysts
- Disease Treatment
- Inflammatory disease therapies
- Nervous system treatments
- Drug development programs
- Research Programs
- Clinical trials
- Pharmaceutical studies
- Drug pipeline development
The company operates under pharmaceutical industry regulations and standards.
Cenyx operates in the pharmaceutical sector with these characteristics:
| Category | Features |
|---|---|
| Technology Platform |
|
| Research Programs |
|
| Regulatory Status |
|
Cenyx maintains its primary operations in South Korea:
- Headquarters
- Seoul, South Korea
- Established 2016
- Research facilities
- Research Activities
- Laboratory operations
- Clinical trial sites
- Development centers
Contact Information:
Cenyx HeadquartersSeoul
South Korea
More details about Cenyx
Innovative biotech solutions at Cenyx
Founded in 2016, Cenyx operates from Seoul, South Korea, as a pioneering biotechnology company. Starting as a cosmetic lab, the company has evolved into a leader in nanomedicine development.
Advanced technological capabilities
At the core of Cenyx’s operations is their proprietary CX synthesis platform, which enables the development of specialized nanozymes. The company has created innovative nano-biotech agents with unique capabilities in managing oxidative stress through the removal of multiple radical compounds.
Research and development focus
- Development of therapeutic nanozymes
- Management of inflammatory conditions
- Nervous system disease treatments
- Advanced enzymatic reaction research
Strategic location in South Korea’s biotech hub
Based in Seoul’s biotechnology district, Cenyx benefits from South Korea’s advanced pharmaceutical research infrastructure. This location positions the company within a network of leading research institutions and medical facilities.
Current developments and achievements
The company maintains four active pipeline programs targeting both acute and chronic inflammatory conditions. In early 2025, Cenyx received orphan designation status, marking a significant milestone in their drug development journey.
Areas of specialization
- Nanozyme technology implementation
- Therapeutic applications development
- Clinical trials management
- Biotech agent optimization
Future directions
Cenyx continues to expand its drug pipeline while strengthening its position in the South Korean biotech sector. The company’s work in nervous system disease treatment represents a growing focus area within their research portfolio.
Company gallery
